Randomized, Double-blind, Placebo-controlled Trial to Determine the Capacity of VAK694 to Elicit Long Term Immune Tolerance When Combined With Subcutaneous Allergen Immunotherapy for the Treatment of Seasonal Allergic Rhinitis.

Trial Profile

Randomized, Double-blind, Placebo-controlled Trial to Determine the Capacity of VAK694 to Elicit Long Term Immune Tolerance When Combined With Subcutaneous Allergen Immunotherapy for the Treatment of Seasonal Allergic Rhinitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs VAK 694 (Primary) ; Grass pollen allergy immunotherapy
  • Indications Grass pollen hypersensitivity; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 31 Oct 2015 Primary endpoint (intra-dermal late phase response to allergen measure: wheal diameter) has been met as per the results published in the Journal of Allergy and Clinical Immunology.
    • 31 Oct 2015 Results published in the Journal of Allergy and Clinical Immunology
    • 24 Apr 2012 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top